Table 4.
Flow cytometry features based on sFLC ratio values.
| Characteristics | Normal sFLC Ratio n = 5 |
Abnormal sFLC Ratio n = 29 |
p Value |
|---|---|---|---|
| Median CD38+CD138+ plasma cells, % (range) | 2 (0.6–15) | 12.2 (0.1–41) | 0.1751 |
| Median lymphocytes, % (range) | 16 (9–35) | 18 (1–35) | 0.9429 |
| Median monocytes, % (range) | 4 (3–7) | 5 (1–11) | 0.8151 |
| Median granulocytes, % (range) | 68 (54–79) | 64 (28–72) | 0.2600 |
| Median CD34+ cells, % (range) | 0.6 (0–1.1) | 0.6 (0.2–1.4) | 0.7571 |
| Plasma cells/residual hemopoiesis | 1.43 (0.2–1.95) | 2.14 (0.3–38.6) | 0.1812 |
| CD56+ plasma cells | 5/5 | 25/27 | >0.9999 |
| CD19+ plasma cells | 2/5 | 4/27 | 0.2779 |
| CD45+ plasma cells | 2/5 | 10/27 | >0.9999 |
| CD56+CD19+CD45+ plasma cells | 1/5 | 0/27 | 0.1562 |
| Double positive plasma cells | 2/5 | 13/27 | >0.9999 |
Abbreviations. PAD, bortezomib, dexamethasone, and doxorubicin; VD, bortezomib and dexamethasone; VRD, bortezomib, lenalidomide, and dexamethasone; VTD.